CD274 and autoimmune disease: The multidisciplinary team takes many factors into account, especially the performance status of the patients, comorbidities—renal insufficiency, chronic cardiac failure, autoimmune diseases, etc., molecular characteristics of the tumor, e.g., expression of programmed-death ligand 1 (PD-L1) either on tumor cells (tumor positive score, TPS) or on both tumor and immune cells in the tumor (combine positive score, CPS), or next-generation sequencing (NGS) results, when deciding the most appropriate treatment approach and assessing the risk of recurrence.